Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study.

ABSTRACT:

Purpose

Ticagrelor is an orally administered, reversibly binding, direct-acting P2Y₁₂ receptor antagonist previously evaluated in several phase III trials. This phase IV, multicenter, single-arm trial assessed the safety and incidence of cardiovascular (CV) events with ticagrelor in Chinese patients experiencing an acute coronary syndrome (ACS).

Methods

Patients hospitalized with an ACS received ticagrelor (180 mg loading dose, 90 mg twice daily thereafter) plus low-dose aspirin (75-100 mg/day) for up to 12 months. Safety was evaluated via PLATO-defined bleeding events, adverse events (AEs), serious AEs, and laboratory measurements. The incidence of major CV events was also evaluated.

Results

The safety population included 2001 patients. During ticagrelor t

SUBMITTER: Gao R 

PROVIDER: S-EPMC5843700 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature